Evidence map›Paper›PMID 38493053›Full record

ReviewAnais brasileiros de dermatologia

Prurigo: review of its pathogenesis, diagnosis, and treatment.

Paulo Ricardo Criado, Mayra Ianhez, Roberta Fachini Jardim Criado, Juliana Nakano, Daniel Lorenzini, Hélio Amante Miot

Open access · goldAbstract readReview
In one paragraph

Review in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Atopic dermatitis.Nature reviews. Disease primers · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Paulo Ricardo CriadoCentro Universitário ABC Faculty of Medicine, Santo André, SP, Brazil; Faculdade de Ciências Médicas de Santos (Fundação Lusíada), Santos, SP, Brazil. Electronic address: prcriado@uol.com.br.
Mayra IanhezDepartment of Dermatology, Hospital de Doenças Tropicais de Goiás, Goiânia, GO, Brazil.
Roberta Fachini Jardim CriadoCentro Universitário ABC Faculty of Medicine, Santo André, SP, Brazil; Alergoskin Alergia e Dermatologia, UCARE Center and ADCARE, Santo André, SP, Brazil.
Juliana NakanoDermatology Outpatient Clinic, Santa Casa de Misericórdia de São Paulo, Brazil.
Daniel LorenziniIrmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil.
Hélio Amante MiotDepartment of Infectious Diseases, Dermatology, Imaging Diagnosis and Radiotherapy, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil.
Irmandade da Santa Casa de Misericórdia de São Paulo · BRCentro Universitário Lusíada · BRFaculdade de Medicina do ABC · BRFundação de Apoio a Pesquisa do Estado de Goiás · BRUniversidade Estadual Paulista (Unesp) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prurigo is a reactive, hyperplastic skin condition characterized by pruritic papules, plaques, and/or nodules. The temporal classification includes acute/subacute and chronic disease (≥ 6 weeks), with different clinical variants, synonymies, and underlying etiological factors. The immunology of chronic prurigo shows similarities with atopic dermatitis due to the involvement of IL-4 and IL-13, IL-22, and IL-31. Treatment includes antihistamines, topical steroids, dupilumab, and JAK inhibitors. Several conditions manifest clinically as prurigo-like lesions, and the correct clinical diagnosis must precede correct treatment. Furthermore, chronic prurigos represent a recalcitrant and distressing dermatosis, and at least 50% of these patients have atopic diathesis, the treatment of which may induce adverse effects, especially in the elderly. The quality of life is significantly compromised, and topical treatments are often unable to control symptoms and skin lesions. Systemic immunosuppressants, immunobiologicals, and JAK inhibitors, despite the cost and potential adverse effects, may be necessary to achieve clinical improvement and quality of life. This manuscript reviews the main types of prurigo, associated diseases, their immunological bases, diagnosis, and treatment.

Indexed as

PrurigoChronic DiseaseHumansQuality of LifeDermatitis, atopicDrug therapyImmunocompromised hostJanus kinase inhibitorsPrurigoPruritus

Identifiers

PMID38493053
PMCPMC11342992
OpenAlexW4392881428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.